Vivimed Labs rose 3.74% to Rs 115.20 at 12:20 IST on BSE after consolidated net profit spurted 810% to Rs 114.75 crore on 25.4% increase in total revenue to Rs 438.96 crore in Q4 March 2017 over Q4 March 2016.
The result was announced on Saturday, 27 May 2017.
Meanwhile, the S&P BSE Sensex was up 68.81 points, or 0.22% at 31,097.02. The S&P BSE Small-Cap index was down 138.51 points, or 0.92% at 14,947.75.
High volumes were witnessed on the counter. On the BSE, 5.04 lakh shares were traded on the counter so far as against the average daily volumes of 2.74 lakh shares in the past one quarter. The stock had hit a high of Rs 127.90 and a low of Rs 114.20 so far during the day.
The stock had hit a record high of Rs 136.40 on 20 April 2017 and hit a 52-week low of Rs 68 on 9 August 2016. The stock had underperformed the market over the past one month till 26 May 2017, declining 5.97% compared with the Sensex's 2.97% rise. The scrip had also underperformed the market over the past one quarter advancing 6.78% as against the Sensex's 7.39% rise.
The small-cap company has equity capital of Rs 16.40 crore. Face value per share is Rs 2.
Vivimed Labs is a niche specialty chemicals and pharmaceuticals company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)